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Abstract
Chronic granulomatous disease is a rare inherited disorder caused by non-existent or severely decreased phagocyte
superoxide production that results in a severe defect in host defense and consequent predisposition to microbial infection.
The enzyme responsible for superoxide production, NADPH oxidase, involves at least five components. An absence of, or a
defect in, any one of four of these proteins (p47phox, p67phox, p22phox and gp91phox) gives rise to the known types of chronic
granulomatous disease. The most common form of inheritance is X-linked and is due to mutations in the CYBB gene that
encodes gp91phox, the large subunit of flavocytochrome b, the terminal electron donor of the oxidase. We have recently
reported a large number of mutations in this gene revealing a broad range of defects, including large and small deletions, and
frameshift, nonsense, missense, splice region and regulatory region mutations. Here we report a patient who has an unusual
type of mutation that results in the generation of a ‘pseudo-exon’ in the gp91phox mRNA and an unexpected pattern of
splicing. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Chronic granulomatous disease (CGD) is a rare
inherited disorder in which phagocytes (neutrophils,
eosinophils, macrophages and monocytes) fail to
undergo a full respiratory burst when stimulated
[1,2]. The products of the respiratory burst, super-
oxide (O32 ) and the reactive oxygen species derived
from it, are critical to the e¡ective destruction of
microorganisms by these cells. Consistent with this
defect, CGD patients su¡er from severe, recurrent
bacterial and fungal infections. In most cases, pa-
tients present early in life with multiple pyogenic in-
fections, but in less severe cases (where there is re-
sidual NADPH oxidase activity), the diagnosis may
occur in adolescence or early adulthood.
The enzyme responsible for the respiratory burst,
NADPH oxidase, is a complex, multicomponent en-
zyme consisting of at least ¢ve components (reviewed
by DeLeo and Quinn [3]). Together, these proteins
form a transmembrane electron transfer system, ca-
pable of oxidizing cytosolic NADPH and reducing
external molecular oxygen to form O32 . This enzyme
is located in the plasma and speci¢c granule mem-
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branes of the cells and is incorporated into the phag-
osome during phagocytosis, thereby directing O32
into the vacuole containing the engulfed microorgan-
ism. Defects in any one of four of the NADPH ox-
idase proteins (p47phox, p67phox, p22phox or gp91phox)
give rise to the known forms of CGD. The most
common form of the disease is X-linked, and results
from mutations in the gp91phox gene (CYBB) that
codes for the L-subunit of £avocytochrome b3245,
the core of NADPH oxidase. The 30-kb CYBB
gene consists of 13 exons and is located at Xp21.1.
Our studies and those of others have revealed a
broad distribution of defects in this gene in patients
with CGD [4^7]. These include small and large dele-
tions, insertions, and point mutations that lead to
premature stop codons, amino acid substitutions,
splice site defects and, rarely, mutations in the 5P
regulatory region. In most cases, the amount of £a-
vocytochrome b3245 is diminished or undetectable in
the patient’s phagocytes. As part of our continuing
characterization of mutations causing CGD, we re-
cently evaluated a patient with the X-linked form of
the disease who had an unusual type of splicing de-
fect.
2. Materials and methods
2.1. Patient
The patient is a 52-year-old male with a history of
recurrent infections from the age of 14 months. He
was diagnosed with CGD at age 24 years. Blood
samples were obtained from the patient and family
members following the procedures approved by the
Human Subjects Committee of The Scripps Research
Institute. Clinical diagnosis of CGD and carrier sta-
tus were con¢rmed by spectrophotometric assay of
the superoxide dismutase-inhibitable rate of cyto-
chrome c reduction, and by £ow cytometry using
dihydrorhodamine as an indicator as previously de-
scribed [7]. Biochemical analysis of the patient’s neu-
trophils showed both an absence of £avocytochrome
b3245 by spectroscopy and the absence of its two
protein components (gp91phox and p22phox) by immu-
noblot. His family history is highly suggestive of X-
linked inheritance, and his mother and sister have
been identi¢ed as carriers by the NBT slide test [8].
2.2. Single-strand conformation polymorphism
(SSCP) analysis
Genomic DNA was extracted from peripheral
blood leukocytes [9]. DNA was analyzed by SSCP
[10,11] utilizing two-stage PCR with 18^27-bp oligo-
nucleotide primers and 100 Wg of genomic DNA,
followed by nested PCR with 33P end-labeled primers
[5]. (Sequences available on request). The resultant
products were subjected to PAGE and detected by
autoradiography. SSCP analysis was performed on
the 5P £anking region and all 13 exons of the
CYBB gene.
2.3. DNA sequencing
DNA sequencing of genomic DNA was performed
as described previously [5] using DNA primers de-
signed to amplify the 5P £anking region and each of
the 13 exons of the CYBB gene from 382 bp 5P of the
coding region to 26 bp 3P of exon 13. The Sanger
dideoxy sequencing method was used.
2.4. mRNA analysis
mRNA was analyzed using RNA isolated from
whole blood using the RNeasy Kit (Qiagen).
cDNA was prepared using RT PCR (Life Technol-
ogy cDNA kit) using a forward primer from exon 1
and a reverse primer from exon 13. The cDNA prod-
ucts were visualized on agarose gels by staining with
ethidium bromide.
3. Results
Analysis by SSCP revealed no abnormalities in the
5P £anking region or any of the 13 exons of the
CYBB gene. In our previous experience, only seven
of 131 kindreds have had mutations undetectable by
SSCP [5], and these were subsequently identi¢ed by
sequencing the entire set of PCR amplicons. We
therefore undertook sequencing of all the exonic re-
gions of genomic DNA, including 382 bp upstream
of the coding region and 26 bp 3P of exon 13. Again,
no abnormalities were found.
To investigate the possibility that intronic abnor-
malities within the CYBB gene result in aberrant
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mRNA transcripts, we analyzed cDNA (prepared
from mRNA isolated from whole blood as described
in Section 2) on agarose gels (Fig. 1). In contrast to
the normal control (lane 1), the patient’s sample con-
tained two cDNA products of approximately equal
abundance (lane 2). One of these species was approx-
imately 50 bp smaller than the normal message (1666
bp) and the other approximately 100 bp larger. Se-
quencing of the two cDNA fragments isolated from
the agarose gels revealed a 94-bp insertion between
exons 6 and 7 in both species. The larger message
was otherwise normal, but the smaller message had
exon 5 deleted in addition to the 94-bp insertion. In
both cases, the mRNA coded for truncated proteins.
We hypothesized that the 94-bp insertion had aris-
en from a splicing abnormality in intron 6. We there-
fore sequenced intron 6 in its entirety (2.4 kb)
by directed sequencing with progressive nucleotide
primers [5] which was accomplished in nine steps.
This analysis disclosed that the 94 bp insertion is
derived from approximately the middle of intron 6.
In 9 normal controls, this sequence is preceded by
taa, but in the patient it is preceded by tag (Fig. 2).
This single nucleotide mutation creates a sequence
with a good match to the consensus 3P (acceptor)
splice site (see Section 4). The sequence following
the 94-bp sequence is gtaatc in both normal and
patient sequences, and represents a consensus 5P
(donor) splice site.
4. Discussion
In the absence of mutations in the coding sequence
and the lack of normal CYBB mRNA transcripts, we
propose that the primary defect in this patient is the
base pair substitution, aCg in intron 6. We believe
this results in the formation of a functional 3P (ac-
ceptor) splice site within the intron. The consensus 3P
Fig. 1. Two abnormal mRNA species of approximately equal
abundance are present in the patient. Analysis of mRNA tran-
scripts of the CYBB gene was performed on agarose gels as de-
scribed in Section 2. Lane 1, normal cDNA, 1666 bp; lane 2,
patient cDNA; upper band V1750 bp, lower band V1600 bp;
lane 3, markers.
Fig. 2. Intron 6 of the patient’s CYBB gene contains a 94-bp sequence resembling an exon. Sequencing of intron 6 (2.4 kb) was per-
formed by gene walking in nine steps. The patient’s DNA has a single base change (aCg, in bold) immediately preceding the 94-bp
sequence that was incorporated into the patient’s mRNA (in uppercase). The proposed donor and acceptor splice sites are marked
with arrows.
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splice site in mammals is a run of approximately 10
pyrimidines; followed by any base (usually c); and
an invariant ag (Fig. 3). Scoring of the patient and
normal sequences by the method of Shapiro and
Senapathy [12] gives an increase in likelihood of their
being an acceptor site from 70.8 to 86.9 as a result of
the substitution aCg. Immediately 3P of the 94 bp
sequence is a consensus donor site, gtaatc, that is
well within the V300-bp maximum for the length
of an exon. The aCg mutation appears to generate
a ‘pseudo-exon’ that is inserted between exons 6 and
7 (Fig. 4, mRNA 1). This ‘pseudo-exon’ ¢ts the
loosely conserved consensus sequence for exons,
starting with G and ending in AG. Due to the incor-
poration of this 94-bp sequence, an mRNA species
V100 nucleotides larger than normal is generated (as
Fig. 3. Consensus sequence elements necessary for correct splicing. The percentage frequency of a particular nucleotide appearing at
each position is indicated by subscript. The percentages are taken from [8]. y = pyrimidine, n = any base.
Fig. 4. Generation of the two abnormal mRNA species in the CGD patient. As described in Section 4, the mutation in intron 6 leads
to the insertion of the 94-bp intronic sequence between exons 6 and 7 (mRNA 1). Approximately half the time, the insertion causes
another splicing error which results in exon 5 being spliced out (mRNA 2).
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shown in Fig. 2). Unexpectedly, approximately half
the time, this new abnormal message results in the
splicing-out of exon 5 (146 bp), presumably due to
conformational restraints imposed by the 94-bp in-
sertion. This leads to the second mRNA species, ap-
proximately 50 nucleotides smaller than normal (Fig.
4, mRNA 2). Searching of the Aberrant Splicing
Database at http://cookie.imcb.osaka-u.ac.jp/nakai/
asdb.html failed to ¢nd a similar type of mRNA
editing error. There are several previous reports of
analogous insertions involving Alu sequences, but, to
the best of our knowledge, this type of event has not
been previously reported for non-Alu sequences. The
generation of novel ‘pseudo-exons’ by this kind of
process could provide an important mechanism of
gene evolution, as well as causing mutations that
lead to inherited diseases.
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